Combined 3D-QSAR, Molecular Docking, and Molecular Dynamics Study on Piperazinyl-Glutamate-Pyridines/Pyrimidines as Potent P2Y12 Antagonists for Inhibition of Platelet Aggregation

An unusually large data set of 397 piperazinyl-glutamate-pyridines/pyrimidines as potent orally bioavailable P2Y(12) antagonists for inhibition of platelet aggregation was studied for the first time based on the combination of three-dimensional quantitative structure-activity relationship (3D-QSAR), molecular docking, and molecular dynamics (MD) methods. The comparative molecular field analysis (CoMFA) and comparative molecular similarity index analysis (CoMSIA) studies have been performed with a training set of 317 compounds, estimating three superimposition methods. The best CoMFA and CoMSIA models, derived from superimposition I, shows leave-one-out cross-validation correlation coefficients (Q(2)) of 0.571 and 0.592 as well as the conventional correlation coefficients (R(2)(ncv)) of 0.814 and 0.834, respectively. In addition, the satisfactory results, based on the bootstrapping analysis and 10-fold cross-validation, further indicate the highly statistical significance of the optimal models. The external predictive abilities of these models were evaluated using a prediction set of 80 compounds, producing the predicted correlation coefficients (R(2)(pred)) of 0.664 and 0.668, respectively. The key amino acid residues were identified by molecular docking, and the stability and rationality of the derived molecular conformations were also validated by MD simulation. The good concordance between the docking results and CoMFA/CoMSIA contour maps provides helpful clues about the rational modification of molecules in order to design more potent P2Y(12) antagonists. We hope the developed models could provide some instructions for further synthesis of highly potent P2Y(12) antagonists.

[1]  V. Fuster,et al.  Atherothrombosis: a widespread disease with unpredictable and life-threatening consequences. , 2004, European heart journal.

[2]  Vishal Prakash Zambre,et al.  Development of predictive pharmacophore model for in silico screening, and 3D QSAR CoMFA and CoMSIA studies for lead optimization, for designing of potent tumor necrosis factor alpha converting enzyme inhibitors , 2010, J. Comput. Aided Mol. Des..

[3]  Ajay N. Jain.  Surflex-Dock 2.1: Robust performance from ligand energetic modeling, ring flexibility, and knowledge-based search , 2007, J. Comput. Aided Mol. Des..

[4]  D. Clement.  A randomised, blinded, trial of Clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE) , 1996 .

[5]  S. Kunapuli,et al.  Coactivation of two different G protein-coupled receptors is essential for ADP-induced platelet aggregation. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[6]  Meryem Köse,et al.  High-affinity, non-nucleotide-derived competitive antagonists of platelet P2Y12 receptors. , 2009, Journal of medicinal chemistry.

[7]  L. Wallentin,et al.  Prasugrel: a novel thienopyridine antiplatelet agent. A review of preclinical and clinical studies and the mechanistic basis for its distinct antiplatelet profile. , 2007, Cardiovascular drug reviews.

[8]  R. Cramer,et al.  Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins. , 1988, Journal of the American Chemical Society.

[9]  D. M. F. Aalten,et al.  PRODRG, a program for generating molecular topologies and unique molecular descriptors from coordinates of small molecules , 1996, J. Comput. Aided Mol. Des..

[10]  B. Hemmateenejad,et al.  A segmented principal component analysis-regression approach to quantitative structure-activity relationship modeling. , 2009, Analytica chimica acta.

[11]  Xue Xu,et al.  Dynamic communication between androgen and coactivator: Mutually induced conformational perturbations in androgen receptor ligand‐binding domain , 2011, Proteins.

[12]  Ajay N. Jain.  Surflex: fully automatic flexible molecular docking using a molecular similarity-based search engine. , 2003, Journal of medicinal chemistry.

[13]  T. Darden,et al.  A smooth particle mesh Ewald method , 1995 .

[14]  Ling Yang,et al.  Classification of Substrates and Inhibitors of P-Glycoprotein Using Unsupervised Machine Learning Approach , 2005, J. Chem. Inf. Model..

[15]  S. Rapp,et al.  Piperazinyl glutamate pyridines as potent orally bioavailable P2Y12 antagonists for inhibition of platelet aggregation. , 2010, Journal of medicinal chemistry.

[16]  Hongmao Sun,et al.  A Universal Molecular Descriptor System for Prediction of LogP, LogS, LogBB, and Absorption , 2004, J. Chem. Inf. Model..

[17]  I. von Kügelgen,et al.  Involvement of basic amino acid residues in transmembrane regions 6 and 7 in agonist and antagonist recognition of the human platelet P2Y(12)-receptor. , 2008, Biochemical pharmacology.

[18]  Vivek Srivastava,et al.  3D-QSAR studies on quinazoline antifolate thymidylate synthase inhibitors by CoMFA and CoMSIA models. , 2010, European journal of medicinal chemistry.

[19]  Jure Zupan,et al.  Kohonen and counterpropagation artificial neural networks in analytical chemistry , 1997 .

[20]  Yuhong Xiang,et al.  3D-QSAR study of hallucinogenic phenylalkylamines by using CoMFA approach , 2007, J. Comput. Aided Mol. Des..

[21]  Yan Li,et al.  Prediction of P2Y12 antagonists using a novel genetic algorithm-support vector machine coupled approach. , 2011, Analytica chimica acta.

[22]  Alexander Golbraikh,et al.  Rational selection of training and test sets for the development of validated QSAR models , 2003, J. Comput. Aided Mol. Des..

[23]  Kenneth A. Solen,et al.  Formation of Occlusive Platelet Aggregates in Whole Blood Caused by Low Concentrations of ADP , 2000, ASAIO journal.

[24]  Chang-Guo Zhan,et al.  Combined 3D-QSAR Modeling and Molecular Docking Study on Indolinone Derivatives as Inhibitors of 3-Phosphoinositide-Dependent Protein Kinase-1 , 2008, J. Chem. Inf. Model..

[25]  Ling Yang,et al.  An in silico approach for screening flavonoids as P-glycoprotein inhibitors based on a Bayesian-regularized neural network , 2005, J. Comput. Aided Mol. Des..

[26]  J. Mccammon,et al.  Computational drug design accommodating receptor flexibility: the relaxed complex scheme. , 2002, Journal of the American Chemical Society.

[27]  H. Horiuchi.  Recent advance in antiplatelet therapy: The mechanisms, evidence and approach to the problems , 2006, Annals of medicine.

[28]  Bahram Hemmateenejad,et al.  Quantitative structure-retention relationship for the Kovats retention indices of a large set of terpenes: a combined data splitting-feature selection strategy. , 2007, Analytica chimica acta.

[29]  Y. Li,et al.  Studies of benzothiadiazine derivatives as hepatitis C virus NS5B polymerase inhibitors using 3D-QSAR, molecular docking and molecular dynamics. , 2010, Current medicinal chemistry.

[30]  Takeshi Hiramoto,et al.  Identification of endogenous surrogate ligands for human P2Y receptors through an in silico search. , 2004, Journal of pharmacological sciences.

[31]  C. Mallari,et al.  A novel P2Y12 adenosine diphosphate receptor antagonist that inhibits platelet aggregation and thrombus formation in rat and dog models , 2007, Thrombosis and Haemostasis.

[32]  J. Maffrand,et al.  ADP Plays a Key Role in Thrombogenesis in Rats , 1988, Thrombosis and Haemostasis.

[33]  G. Klebe,et al.  Molecular similarity indices in a comparative analysis (CoMSIA) of drug molecules to correlate and predict their biological activity. , 1994, Journal of medicinal chemistry.

[34]  Francesca Deflorian,et al.  Comparison of three GPCR structural templates for modeling of the P2Y12 nucleotide receptor , 2011, J. Comput. Aided Mol. Des..

[35]  R. Cramer,et al.  Validation of the general purpose tripos 5.2 force field , 1989 .

[36]  J. Laitinen,et al.  2-Alkylthio-substituted platelet P2Y12 receptor antagonists reveal pharmacological identity between the rat brain Gi-linked ADP receptors and P2Y12 , 2003, Neuropharmacology.

[37]  Wei Yang,et al.  Mechanism of MicroRNA-Target Interaction: Molecular Dynamics Simulations and Thermodynamics Analysis , 2010, PLoS Comput. Biol..

[38]  D. van der Spoel,et al.  GROMACS: A message-passing parallel molecular dynamics implementation , 1995 .

[39]  N. Fujita,et al.  Identification of endogenous surrogate ligands for human P2Y12 receptors by in silico and in vitro methods. , 2005, Biochemical and biophysical research communications.

[40]  P. Leeson,et al.  From ATP to AZD6140: the discovery of an orally active reversible P2Y12 receptor antagonist for the prevention of thrombosis. , 2007, Bioorganic & medicinal chemistry letters.

[41]  S. Kunapuli,et al.  Molecular Basis for ADP-induced Platelet Activation , 1998, The Journal of Biological Chemistry.

[42]  S. Morgan,et al.  Outlier detection in multivariate analytical chemical data. , 1998, Analytical chemistry.

[43]  Deepak L. Bhatt,et al.  Clinical Aspects of Platelet Inhibitors and Thrombus Formation , 2007, Circulation research.

[44]  Alexander Golbraikh,et al.  Predictive QSAR modeling based on diversity sampling of experimental datasets for the training and test set selection , 2002, J. Comput. Aided Mol. Des..

[45]  David Julius,et al.  Identification of the platelet ADP receptor targeted by antithrombotic drugs , 2001, Nature.

[46]  Jun Ding,et al.  Classification of bioaccumulative and non-bioaccumulative chemicals using statistical learning approaches , 2008, Molecular Diversity.

[47]  M. Mohsennia,et al.  Prediction of lambda(max) of 1,4-naphthoquinone derivatives using ant colony optimization. , 2010, Analytica chimica acta.

[48]  J. Morser,et al.  Novel P2Y12 adenosine diphosphate receptor antagonists for inhibition of platelet aggregation (I): in vitro effects on platelets. , 2008, Thrombosis research.

[49]  J. Boyer,et al.  Adenosine analogues as inhibitors of P2Y12 receptor mediated platelet aggregation. , 2008, Bioorganic & medicinal chemistry letters.

[50]  T. Kikuchi,et al.  Construction of Hypothetical Three-Dimensional Structure of P2Y1 Receptor Based on Fourier Transform Analysis , 2002, Journal of protein chemistry.

[51]  K. Chou.  Structural bioinformatics and its impact to biomedical science. , 2004, Current medicinal chemistry.

[52]  A. Tropsha,et al.  Beware of q2! , 2002, Journal of molecular graphics & modelling.

[53]  Masafumi Ueno,et al.  Cangrelor: a review on its mechanism of action and clinical development , 2009, Expert review of cardiovascular therapy.

[54]  Rui M. V. Abreu,et al.  QSAR model for predicting radical scavenging activity of di(hetero)arylamines derivatives of benzo[b]thiophenes. , 2009, European journal of medicinal chemistry.

[55]  S. Rapp,et al.  Piperazinyl-glutamate-pyrimidines as potent P2Y12 antagonists for inhibition of platelet aggregation. , 2009, Bioorganic & medicinal chemistry letters.

[56]  Yonghua Wang,et al.  Understanding the Aquatic Toxicity of Pesticide: Structure‐Activity Relationship and Molecular Descriptors to Distinguish the Ratings of Toxicity , 2009 .

[57]  G Klebe,et al.  Three-dimensional quantitative structure-activity relationship analyses using comparative molecular field analysis and comparative molecular similarity indices analysis to elucidate selectivity differences of inhibitors binding to trypsin, thrombin, and factor Xa. , 1999, Journal of medicinal chemistry.

[58]  R. Vergona,et al.  Novel P2Y12 adenosine diphosphate receptor antagonists for inhibition of platelet aggregation (II): pharmacodynamic and pharmacokinetic characterization. , 2008, Thrombosis research.

[59]  M. Shamsipur,et al.  Comparative QSAR Studies on Toxicity of Phenol Derivatives Using Quantum Topological Molecular Similarity Indices , 2010, Chemical biology & drug design.

[60]  Berk Hess,et al.  GROMACS 3.0: a package for molecular simulation and trajectory analysis , 2001 .

[61]  Yan Li,et al.  In silico Prediction of Androgenic and Nonandrogenic Compounds Using Random Forest , 2009 .

[62]  Hongmao Sun,et al.  Prediction of Chemical Carcinogenicity from Molecular Structure , 2004, J. Chem. Inf. Model..

[63]  Hongma Sun,et al.  Pharmacophore-based virtual screening. , 2008, Current medicinal chemistry.

[64]  J. Herbert,et al.  Identification and Biological Activity of the Active Metabolite of Clopidogrel , 2000, Thrombosis and Haemostasis.

[65]  Jonas Boström,et al.  A novel series of piperazinyl-pyridine ureas as antagonists of the purinergic P2Y12 receptor. , 2011, Bioorganic & medicinal chemistry letters.

[66]  M. Parrinello,et al.  Polymorphic transitions in single crystals: A new molecular dynamics method , 1981 .

[67]  K. Jacobson,et al.  Architecture of P2Y nucleotide receptors: structural comparison based on sequence analysis, mutagenesis, and homology modeling. , 2004, Journal of medicinal chemistry.

[68]  G. Spalluto,et al.  6-Amino-2-mercapto-3H-pyrimidin-4-one derivatives as new candidates for the antagonism at the P2Y12 receptors. , 2009, Bioorganic & medicinal chemistry.

[69]  V. Fuster,et al.  Atherothrombosis: mechanisms and clinical therapeutic approaches , 1998, Vascular medicine.

[70]  Gerhard Bringmann,et al.  3D QSAR Investigations on Antimalarial Naphthylisoquinoline Alkaloids by Comparative Molecular Similarity Indices Analysis (CoMSIA), Based on Different Alignment Approaches , 2003, J. Chem. Inf. Comput. Sci..

[71]  Kevin P. Bliden,et al.  Clopidogrel for Coronary Stenting Response Variability, Drug Resistance, and the Effect of Pretreatment Platelet Reactivity , 2003, Circulation.

[72]  J. Gasteiger,et al.  ITERATIVE PARTIAL EQUALIZATION OF ORBITAL ELECTRONEGATIVITY – A RAPID ACCESS TO ATOMIC CHARGES , 1980 .

[73]  S. Wold,et al.  The Collinearity Problem in Linear Regression. The Partial Least Squares (PLS) Approach to Generalized Inverses , 1984 .

[74]  M. Shamsipur,et al.  EXPLORING QSAR FOR THE INHIBITORY ACTIVITY OF A LARGE SET OF AROMATIC /HETEROCYCLIC SULFONAMIDES TOWARD FOUR DIFFERENT ISOENZYMES OF CARBONIC ANHYDRASE , 2007 .